Hitting a soft drug with a hard nucleophile: Preparation of esmolol's metabolite by treatment with bis(tributyltin) oxide

Synthetic Communications

Volumn 42, Issue 5, 2012, Pages 722-726

  Zhang, Cunyu A ^a   Erhardt, Paul W ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Bis(tributyltin) oxide; Esmolol metabolite; Ester hydrolysis; Synthesis

Indexed keywords

ACETIC ACID ETHYL ESTER; AMINE; CARBOXYLIC ACID DERIVATIVE; DRUG METABOLITE; ESMOLOL; TRIBUTYLTIN;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; DRUG SYNTHESIS; EVAPORATION; HYDROLYSIS;

EID: 80755171436     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397911.2010.530375     Document Type: Article

References (16)

1. Erhardt, P. W. Medicinal chemistry in the new millennium: A glance into the future. J. Pure Appl. Chem. 2002, 74, 703-785.
2. Erhardt, P. W.; Proudfoot, J. R. Drug discovery: Historical perspective, current status and outlook; In Comprehensive Medicinal Chemistry II; J. Taylor, D. Triggle (Eds.); Elsevier: Oxford, UK, 2007; vol. 1, pp. 29-96.
3. Erhardt, P. W. Drug discovery; In Pharmacology: Principles and practice; M. Hacker, W. Messer, K. Bachmann (Eds.); Elsevier: Oxford, UK, 2009; pp. 475-560.
4. Erhardt, P. W.; Khupse, R.; Sarver, J. G.; Trendel, J. A. Prodrugs: Strategic deployment, metabolic considerations, and chemical design principles; In Burger's Medicinal Chemistry, Drug Discovery, and Development; D. Abraham (Ed.); John Wiley & Sons: Hoboken, NJ, 2010, pp. 103-150.
5. Bodor, N.; Buchwald, P. Soft drug design: General principles and recent applications. Med. Res. Rev. 2000, 20, 58-101. (Pubitemid 30027561)
6. Erhardt, P. W.; Reese, M. D. Soft drugs; In Prodrugs and Targeted Delivery; J. Rautio (Ed.); Wiley-VCH: Weinheim, Germany, 2011, pp. 385-413.
7. Erhardt, P. W. Drug metabolism data: Past, present, and future considerations; In Drug Metabolism: Databases and High-Throughput Testing during Drug Design and Development;
8. P. W. Erhardt (Ed.); IUPAC=Blackwell: Geneva, Switzerland, 1999; pp. 2-15.
9. Erhardt, P. W. Esmolol. Chronicles of Drug Discovery 1993, 3, 191-206.
10. Erhardt, P. W. Case study: "Esmolol stat"; In Analog-Based Drug Discovery; J. Fischer, R. Ganellin (Ed.); Wiley-VCH: Weinheim, Germany, 2006; pp. 233-246.
11. van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44, 1313-1333. (Pubitemid 32852106)
12. Liao, J. Development of soft drugs for the neonatal population. M.S. thesis, University of Toledo, Toledo, Ohio, USA, 2000.
13. Fang, L. Stereoselective synthesis of esmolol and in vitro pharmacokinetic study of esmolol and its acid metabolite. M.S. thesis, University of Toledo, Toledo, Ohio, USA, 2009.
14. Reese, M. Drug design (STAT5 modulators), development (glyceollin I), and improvement (esmolol plus). M.S. thesis, University of Toledo, Toledo, Ohio, USA, 2009.
15. Erhardt, P. W.; Woo, C. M.; Anderson, W. G.; Gorczynski, R. J. Ultra-short-acting β-adrenergic receptor blocking agents, 2: (Aryloxy)propanolamines containing esters on the aryl function. J. Med. Chem. 1982, 25, 1408-1412. (Pubitemid 13212466)
16. Salomon, C. J.; Mata, E. G.; Mascaretti, O. A. Scope and mechanism of deprotection of carboxylic esters by bis(tributyltin) oxide. J. Org. Chem. 1994, 59, 7259-7266.